Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China.
The Third Bethune Hospital of Jilin University, Changchun, China.
Front Immunol. 2023 Dec 6;14:1270011. doi: 10.3389/fimmu.2023.1270011. eCollection 2023.
Multi-antibody-positive myasthenia gravis (MG) presentations are relatively rare, often found in older patients, and generally predict a poor prognosis. We report a case of a female patient with generalized MG, testing positive for Titin antibodies (Titin-Ab), ryanodine receptor antibodies (RyR-Ab), and acetylcholine receptor antibodies (AChR-Ab), and resistant to acetylcholinesterase inhibitors. Following unsuccessful traditional therapies, she received Telitacicept, leading to significant improvements. This case underscores Telitacicept's potential efficacy for similar patients and offers insights into the clinical characteristics of multi-antibody MG.
多抗体阳性重症肌无力(MG)较为罕见,常发生于老年患者,且一般预示预后不良。我们报告一例全身型 MG 女性患者,其 Titin 抗体(Titin-Ab)、兰尼碱受体抗体(RyR-Ab)和乙酰胆碱受体抗体(AChR-Ab)阳性,且对乙酰胆碱酯酶抑制剂耐药。在传统治疗无效后,她接受了 Telitacicept 治疗,病情显著改善。该病例突出了 Telitacicept 对类似患者的潜在疗效,并为多抗体 MG 的临床特征提供了见解。